New RSV protections for infants hit cost, insurance hurdles in U.S. rollout

Pfizer's maternal vaccine, Abrysvo, and Sanofi's monoclonal antibody, Beyfortus, were approved for expectant mothers and infants in the U.S. earlier this year.

from Health and Science https://ift.tt/ej3kHtf
https://ift.tt/81UPu96
https://ift.tt/sUMzlT8